Abstract:Tumor-associated macrophages (TAMs) are predominantly present in the tumor microenvironment (TME) and play a crucial role in shaping the efficacy of tumor immunotherapy. These TAMs primarily exhibit a tumor-promoting M2-like phenotype, which is associated with the suppression of immune responses and facilitation of tumor progression. Interestingly, recent research has highlighted the potential of repolarizing TAMs from an M2 to a pro-inflammatory M1 status-a shift that has shown promise in impeding tumor growth and enhancing immune responsiveness. This concept is particularly intriguing as it offers a new dimension to cancer therapy by targeting the tumor microenvironment, which is a significant departure from traditional approaches that focus solely on tumor cells. However, the clinical application of TAM-modulating agents is often challenged by issues such as insufficient tumor accumulation and off-target effects, limiting their effectiveness and safety. In this regard, nanomaterials have emerged as a novel solution. They serve a dual role: as delivery vehicles that can enhance the accumulation of therapeutic agents in the tumor site and as TAM-modulators. This dual functionality of nanomaterials is a significant advancement as it addresses the key limitations of current TAM-modulating strategies and opens up new avenues for more efficient and targeted therapies. This review provides a comprehensive overview of the latest mechanisms and strategies involving nanomaterials in modulating macrophage polarization within the TME. It delves into the intricate interactions between nanomaterials and macrophages, elucidating how these interactions can be exploited to drive macrophage polarization towards a phenotype that is more conducive to anti-tumor immunity. Additionally, the review explores the burgeoning field of TAM-associated nanomedicines in combination with tumor immunotherapy. This combination approach is particularly promising as it leverages the strengths of both nanomedicine and immunotherapy, potentially leading to synergistic effects in combating cancer.

Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy

Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

Nanomaterials targeting tumor associated macrophages for cancer immunotherapy

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy

Macrophage-modulating nanomedicine for cancer immunotherapy

Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles

Advance of nano anticancer therapies targeted on tumor-associated macrophages

Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Harnessing Anti‐tumor and Tumor‐tropism Functions of Macrophages Via Nanotechnology for Tumor Immunotherapy

Targeting tumor-associated macrophages for cancer treatment

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy

Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression

Recent Progress on Nanomedicine-Mediated Repolarization of Tumor-Associated Macrophages for Cancer Immunotherapy

Reprogramming Tumor Associated Macrophages Toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy

Tumor Associated Macrophages and TAMs‐Based Anti‐Tumor Nanomedicines

A Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.